Monday, August 31, 2009
Heat Biologics Inc. believes that its heat shock protein technology for
cancer immunotherapy may have an advantage over competitors because it exposes
the immune system to all of a cancer's antigens, whereas other treatments only
use a select number of antigens.
Heat's lead therapy is
HeatShock gp96-Ig, which is in Phase I/II testing for non-small cell lung
cancer (NSCLC). The therapy involves the intra-dermal injection of a live
attenuated, immortalized NSCLC tumor cell that has been engineered to function
as a vaccine-producing cell.